AstraZeneca Bets $25M On Preclinical Bispecific Antibody

  • Harbour BioMed has announced a global out-license agreement with AstraZeneca plc AZN for CLDN18.2xCD3 bispecific antibody (HBM7022).
  • HBM7022 is a novel bispecific antibody generated from HBM's HCAb Based Immune Cell Engagers (HBICE) Platform. 
  • HBM7022 is currently in the preclinical stage, which crosslinks tumor cells and T cells by targeting a tumor-associated antigen (Claudin18.2) and CD3 and thus leads to potent T cell activation and tumor elimination.
  • According to HBM, the candidate has shown efficacy against Claudin18.2-positive gastric cancer, both in its wild type and mutated forms, and pancreatic cancer. The evidence of efficacy comes from preclinical studies.
  • AstraZeneca will be granted an exclusive global license for the research, development, registration, manufacturing, and commercialization of HBM7022 and shall be solely responsible for all costs and activities associated with its further development and commercialization.
  • HBM shall receive an upfront payment of $25 million with the potential milestone payments of up to $325 million.
  • Price Action: AZN shares are up 1.73% at $70.27 during the market session on the last check Thursday.

Posted In: BriefsBiotechNewsHealth CareContractsGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.